Top-News
Pharmazeutika Frankreich

Sanofi-Aventis SA ADR News

Aktie
WKN:  662283 ISIN:  US80105N1054 US-Symbol:  SNY
45,20 €
-0,60 €
-1,31%
06.05.24 17:00:59
Handeln Depot/Watchlist
Aktienanzahl *
2,50 Mrd.
Marktkapitalisierung *
113,85 Mrd. €
Streubesitz
-
Faktor
2
Originalaktie
FR0000120578
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 25.04.2024

Sanofi-Aventis SA ADR News

01.02.24 - wallstreet:online Zentralredaktion
Ihre wichtigsten Termine: Alle Blicke auf: Apple, Meta, Altria, Merck, Shell und Siemens Healthineers
Gut geplant in den Tag. Mit dem w:o-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
23.01.24 - PR Newswire
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B PR Newswire
02.11.23 - PR Newswire
Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities
Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities PR Newswire
01.11.23 - PR Newswire
Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.
Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S. PR Newswire
10.10.23 - PR Newswire
Stagwell's (STGW) The Harris Poll Unveils First-of-its-kind Global Hemophilia Survey on the Daily Challenges for Patients, Caregivers, and Providers
Stagwell's (STGW) The Harris Poll Unveils First-​of-its-kind Global Hemophilia Survey on the Daily Challenges for Patients, Caregivers, and Providers PR Newswire
13.09.23 - PR Newswire
Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu PR Newswire
25.07.23 - PR Newswire
Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact PR Newswire
20.06.23 - PR Newswire
Thinking about trading options or stock in NVIDIA, Baidu, Lumentum Holdings, Sanofi, or AMC Entertainment?
Thinking about trading options or stock in NVIDIA, Baidu, Lumentum Holdings, Sanofi, or AMC Entertainment? PR Newswire
18.05.23 - PR Newswire
Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi
Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi PR Newswire
04.04.23 - PR Newswire
Sanofi Breaks Ground on State-of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines
Sanofi Breaks Ground on State-​of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines PR Newswire
23.03.23 - PR Newswire
Thinking about trading options or stock in Sanofi, Alibaba, Microsoft, NVIDIA, or Accenture?
Thinking about trading options or stock in Sanofi, Alibaba, Microsoft, NVIDIA, or Accenture? PR Newswire
18.01.23 - PR Newswire
Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare
Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare PR Newswire
21.12.22 - PR Newswire
Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine PR Newswire
15.12.22 - PR Newswire
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis PR Newswire
11.11.22 - PR Newswire
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis PR Newswire
06.10.22 - PR Newswire
Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
Sanofi US enters into co-​promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-​modifying therapy for type 1 diabetes PR Newswire
28.09.22 - PR Newswire
Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis PR Newswire
05.09.22 - PR Newswire
Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Late-​Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-​to-severe ...
26.08.22 - PR Newswire
Sanofi higher dose flu vaccines preferentially recommended for adults 65+ in CDC Morbidity and Mortality Weekly Report
Sanofi higher dose flu vaccines preferentially recommended for adults 65+ in CDC Morbidity and Mortality Weekly Report PR Newswire
12.08.22 - PR Newswire
Public health experts underscore importance of flu vaccinations to help reduce health inequities among high-risk populations
Public health experts underscore importance of flu vaccinations to help reduce health inequities among high-risk populations PR Newswire

Newssuche

Videos

newspaper
06.05.24 +2,22%
Technical Trading: Rohöl Short Chance
Rohöl Short Typ: Turbo Open End WKN: VD4JF9 Hebel: 13 Laufzeit: OpenEnd Einstieg: Market ... Mehr »